HAE Haemonetics
Haemonetics earnings company data as of 3:59 PM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 1.30 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by HAE's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $99K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Mark W Kroll DirectorBuy$99K 1,400 shares at $70.56 +6% to stakeTraded Nov 10, 2025 Filed Nov 12, 2025
Also filed in the last 12 months, not counted as buying or selling: 15 stock grants and 11 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 22 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01 | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 7.01,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.